NCT01504581View on ClinicalTrials.gov

Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2011

Conditions
Healthy
Interventions
BIOLOGICAL

HM10660A

Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg

BIOLOGICAL

HM10660A placebo

Single dose of HM10660A Placebo

BIOLOGICAL

Pegasys

Single dose of Pegasys 180ug

Trial Locations (1)

Unknown

Hanmi clinical, Netherlands

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01504581 - Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter